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Abstract
Neoadjuvant chemotherapy (NAC) for breast cancer is widely employed and we performed 
genome-wide association studies (GWAS) to determine if germline genetic variability was 
associated with benefit in terms of pathological complete response (pCR), disease-free survival 
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(DFS), and overall survival (OS) in patients entered on the NSABP B-40 NAC trial where patients 
were randomized to receive, or not, bevacizumab in addition to chemotherapy. Patient DNA 
samples were genotyped with the Illumina OmniExpress BeadChip. Replication was attempted 
with genotyping data from 1398 HER2-negative patients entered on the GeparQuinto NAC study 
in which patients were also randomized to receive, or not, bevacizumab in addition to 
chemotherapy. 920 women from B-40 were analyzed and 237 patients achieved a pCR. GWAS 
with three phenotypes (pCR, DFS, OS) revealed no SNPs that were genome-wide significant (i.e., 
p≤5E-08) signals; p-values for top SNPs were 2.04E-07, 5.61E-08, and 5.63E-08, respectively, and 
these SNPs were not significant in the GeparQuinto data. An ad hoc GWAS was performed in the 
patients randomized to bevacizumab (457 patients with 128 pCR) that showed signals on 
chromosome 6, located within a gene, CDKAL1, that approached, but did not reach, genome-wide 
significance (top SNP rs7453577, p=2.97E-07). However, this finding was significant when tested 
in the GeparQuinto dataset (p=0.04). In conclusion, we identified no SNPs significantly associated 
with NAC. The observation, in a hypothesis-generating GWAS, of a SNP in CDKAL1 associated 
with pCR in the bevacizumab arm of both B-40 and GeparQuinto requires further validation and 
study.
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Introduction
There is increasing use of neoadjuvant chemotherapy (NAC) in the management of early-
stage breast cancer(1). Based on the importance of angiogenesis in breast cancer 
progression(2) and promising results from early studies of bevacizumab, a monoclonal 
antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A 
(VEGF-A), in metastatic breast cancer(3), multiple clinical trials in the neoadjuvant setting 
were conducted. Four of these trials have reported results, including NSBAP B-40(4, 5), 
GeparQuinto(6, 7), CALGB 40603(8), and the ARTemis trial(9).
Achievement of a pathological complete response (pCR), with complete eradication of 
invasive breast cancer in the breast and nodes, has been associated with improved survival 
with the greatest prognostic value in aggressive tumor subtypes(10). We hypothesized that 
there are genes related to the achievement of a pCR in women treated with NAC with or 
without bevacizumab, and that we would be able to identify germ-line genetic variation 
measured as single nucleotide polymorphisms (SNPs) associated with pCR with a genome-
wide association study (GWAS) utilizing B-40(4) and attempting replication with HER2-
negative patients entered on GeparQuinto(6).
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Methods
Source of Patients
All patients with HER2-negative early breast cancer entered on NSABP B-40 (schema: 
Supplementary Figure 1) with a blood sample for DNA extraction and consent for genetic 
testing were eligible following Mayo IRB review.
Definition of Phenotype
The pCR definition was the complete eradication of all invasive breast cancer in both the 
breast and regional nodes.
Study Design
Anonymized samples were sent to Mayo Clinic for DNA extraction, were plated, and sent to 
the RIKEN Center for Integrative Medical Science for genotyping. The clinical and 
genotyping data were then analyzed at Mayo Clinic. The primary objective was to identify 
genetic variation measured as SNPs associated with pCR with a GWAS. Secondary 
objectives were to explore the association of SNPs with outcomes, i.e., disease-free survival 
(DFS) and overall survival (OS). An ad hoc exploratory GWAS was performed with the 
phenotype of pCR in patients randomized to bevacizumab.
Genotyping, quality control, and imputation
Genotyping was performed with the Illumina HumanOmniExpressExome BeadChips. 
Details regarding genotyping, quality control, and imputation are given the Supplementary 
Material.
The data from this GWAS have been deposited in the Data Base of Genotypes and 
Phenotypes (dbGaP). The dbGaP Study Accession Number is phs001365.v1.p1 and the 
URL is https://www.ncbi.nlm.nih.gov/projects/gapprev/gap/cgi-bin/preview1.cgi?
GAP_phs_code=DlBPhGnsRxXYbJZW.
Statistical analysis
The primary analyses were based on logistic regression with SNP genotypes analyzed as 
log-additive effects on the chance of a pCR. The primary covariates that were adjusted for 
include treatment arm and any other clinical factors found to be associated with pCR (at p-
value < 0.10). To control for potential population stratification, we used the program 
STRUCTURE and HapMap racial groups to determine additional covariates. We utilized 
EigenStrat to determine the eigen values for the SNP correlation matrix that statistically 
differed from zero(11, 12). To evaluate the association of SNPs with DFS and OS, we used 
the Cox proportional hazards model, including covariates to adjust for patient heterogeneity.
Replication
Replication of top SNPs from the four GWAS (pCR, DFS, OS, and pCR in bevacizumab 
patients) was attempted utilizing genotyping data from patients with HER2-negative early 
breast cancer entered on GeparQuinto (schema: Supplementary Figure 2, Supplementary 
Ingle et al. Page 3
Pharmacogenet Genomics. Author manuscript; available in PMC 2019 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Table). Details regarding genotyping, quality control, imputation, and sample cohorts for 
individual GWAS of GeparQuinto are given in the Supplementary Material.
Results
Patients studied
The participant flow diagram (Supplementary Figure 3) shows the B-40 patients included 
and excluded from the four GWAS with the phenotypes of 1) pCR, 2) DFS, 3) OS, and 4) 
pCR in bevacizumab-treated patients only. Supplementary Figure 4 shows the GeparQuinto 
patients included in the replication studies.
GWAS with phenotype of PCR
Table 1 shows the clinical summary of the 914 patients in the primary analysis. The analysis 
was adjusted for treatment (bevacizumab, no bevacizumab), race, completion of neoadjuvant 
chemotherapy, and tumor grade in addition to being stratified for categorical-age, ER/PR 
status, tumor size and nodal stage. The distribution of p-values is shown in the Manhattan 
plot (Figure 1A) and locus zoom (Supplementary Figure 5A) and revealed the top SNP 
(rs34843881, imputed) on chromosome 13 to have a p-value of 2.04E-07, which did not 
reach genome-wide statistical significance (Table 2). The Quantile-Quantile (QQ) plot for 
the conditional logistic regression results is shown in Supplementary Figure 6A. The top 
SNP was examined in GeparQuinto and showed p=0.73 (Table 2), indicating this was not an 
important signal.
GWAS with phenotype of disease-free survival
The GWAS with the phenotype of DFS was performed with 890 patients since 24 of the 914 
patients were removed due to missing outcome data and/or tumor grade. A DFS event 
occurred in 219 (24.6%) of the patients. Stepwise analysis showed clinical variables such as 
treatment, tumor grade, and completion of neoadjuvant chemotherapy were associated with 
DFS and these variables were controlled for in the analysis, in addition to race. The 
Manhattan plot (Figure 1B) and locus zoom (Supplementary Figure 5B) revealed the top 
SNP (rs78269823, imputed) on chromosome 14 to have a p-value of 5.61E-08, which 
approached but did not reach genome-wide significance. The QQ plot is shown in 
Supplementary Figure 6B. The top SNP was examined in GeparQuinto and showed p=0.76 
(Table 2), indicating this was not an important signal.
GWAS with phenotype of overall survival
The GWAS with the phenotype of OS was performed with 891 patients of whom 
144(16.1%) had died. The model was controlled by the same variables as for DFS. The 
Manhattan plot (Figure 1C) and locus zoom (Supplementary Figure 5C) revealed the top 
SNP (rs56330643, imputed) on chromosome 14 to have a p-value of 5.63E-08, which 
approached but did not reach genome-wide significance. The QQ-plot is shown in 
Supplementary Figure 6C). The top SNP was examined in GeparQuinto and showed p=0.50 
(Table 2), indicating this was not an important signal.
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Exploratory GWAS in patients who received bevacizumab
The GWAS with the phenotype of pCR was performed with 447 patients who had received 
bevacizumab of whom 147 (32.8%) had achieved a pCR. The model was controlled for the 
stratification variables noted above, race, and tumor grade. The Manhattan plot (Figure 1D) 
and locus zoom (Supplementary Figure 5D) revealed the top SNP, (rs7453577, imputed) to 
have a p-value of 2.97E-07. The QQ plot is shown in Supplementary Figure 6D. The top 
SNP was examined in GeparQuinto and showed p=0.04 (Table 2), which achieved statistical 
significance.
Given the findings from GeparQuinto, we examined this area more closely. In the B-40 
GWAS, there were a total of 17 SNPs in addition to the top SNP in a gene, CDKAL1 
(CDK5 Regulatory Subunit Associated Protein 1 Like 1), with p-values ranging from 
3.11E-07 to 8.63E-07. Included in these SNPs was a single genotyped SNP, rs1004172, with 
p=3.73E-07. The MAFs of these SNPs were 0.19–0.22.
Discussion
The primary objective of this study was to identify any association between germ-line 
genetic variation and pCR in women receiving NAC in B-40. The top SNP (rs34843881) did 
not achieve genome-wide significance (p=2.04 E-07). When this SNP was examined in 
GeparQuinto database there was no evidence of any association (p=0.73).
Secondary objectives were to identify any association between germ-line genetic variation 
and the outcomes of DFS and OS in women receiving NAC. The top SNPs from B-40 
almost reached genome-wide significance, p-value accepted to be 5E-08, i.e., 5.61E-08 and 
5.63E-08, respectively. However, when examined in GeparQuinto, the p-values were not 
replicated, being p=0.76 and p=0.50, respectively.
Because those studies reported a significantly higher pCR rate in the patients randomized to 
bevacizumab, we performed an exploratory GWAS only in the patients who received 
bevacizumab. The top SNP (rs7453577) had a p-value of 2.97E-07 in B40 and when 
examined in GeparQuinto was significant (p=0.04). Given that this was an ad hoc analysis, it 
must be considered hypothesis generating. The top SNP was located in CDKAL1, which 
encodes a protein that is a member of the methylthiotransferase family. The function of this 
gene is not known, but prior GWAS have linked SNPs in an intron of CDKAL1 with 
susceptibility to type II diabetes(13).
Ideally, a replication study should be identical to a discovery study. Whereas B-40 and 
GeparQuinto have substantial similarities, they also have differences. The anthracycline 
utilized was different being doxorubicin in B-40 and epirubicin in GeparQuinto. The 
sequencing of the anthracycline and taxane was opposite and the duration of bevacizumab 
therapy was different in the two studies. Patients were taken off study if a response was not 
seen after the 4 cycles of the anthracycline plus cyclophosphamide in the GeparQuinto 
study. Also, in B-40, bevacizumab had a significantly higher pCR rate in ER-positive 
patients whereas in GeparQuinto the bevacizumab had a significantly higher pCR rate in 
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ER-negative patients. These differences demonstrate that in pharmacogenomics, the 
identification of an ideal replication study can be difficult.
Conclusions
We performed GWAS in a major NAC study and did not find a significant association 
between germ-line genetic variation and pCR, DFS, or OS. The observation of a SNP in 
CDKAL1 associated with pCR in the bevacizumab arm of both B40 and GeparQuinto 
requires further validation and study.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Manhattan plots of p-values for conditional logistic regression analysis of the NSABP B-40 
trial for A) pathologic complete response (pCR), B) disease-free survival, C) overall 
survival, and D) pCR in bevacizumab-treated patients only.
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Table 1
NSABP B-40 Clinical Summary
No Bevacizumab (N=459) Bevacizumab (N=455) Total (N=914)
Age at Randomization
 Median 49.0 48.0 49.0
 Q1, Q3 41.0, 56.0 42.0, 56.0 41.0, 56.0
 Range (25.0–70.0) (24.0–71.0) (24.0–71.0)
pCR Breast and Nodes
 No 350 (76.3%) 328 (72.1%) 678 (74.2%)
 Yes 109 (23.7%) 127 (27.9%) 236 (25.8%)
Gemcitabine
 No 314 (68.4%) 305 (67.0%) 619 (67.7%)
 Yes 145 (31.6%) 150 (33.0%) 295 (32.3%)
Capecitabine
 No 303 (66.0%) 301 (66.2%) 604 (66.1%)
 Yes 156 (34.0%) 154 (33.8%) 310 (33.9%)
Bevacizumab
 No 459 (100.0%) 0 (0.0%) 459 (50.2%)
 Yes 0 (0.0%) 455 (100.0%) 455 (49.8%)
Clinical Tumor Status
 2–4cm 212 (46.2%) 202 (44.4%) 414 (45.3%)
 >4cm 247 (53.8%) 253 (55.6%) 500 (54.7%)
Clinical Nodal Status
 Negative 243 (52.9%) 251 (55.2%) 494 (54.0%)
 Positive 216 (47.1%) 204 (44.8%) 420 (46.0%)
Hormone Receptor Status
 Negative 197 (42.9%) 193 (42.4%) 390 (42.7%)
 Positive 262 (57.1%) 262 (57.6%) 524 (57.3%)
Estrogen Receptor/Progesterone Receptor
 Negative/Negative 197 (43.2%) 193 (42.4%) 390 (42.8%)
 Negative/Positive 8 (1.8%) 9 (2.0%) 17 (1.9%)
 Positive/Negative 40 (8.8%) 47 (10.3%) 87 (9.5%)
 Positive/Positive 211 (46.3%) 206 (45.3%) 417 (45.8%)
 Positive/unknown 3 (0.6%) 0 3 (0.3%)
Histologic Tumor Grade
 Well 33 (7.2%) 30 (6.6%) 63 (6.9%)
 Moderate 149 (32.5%) 160 (35.2%) 309 (33.8%)
 Poor 269 (58.6%) 261 (57.4%) 530 (58.0%)
 Unknown 8 (1.7%) 4 (0.9%) 12 (1.3%)
Breast
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No Bevacizumab (N=459) Bevacizumab (N=455) Total (N=914)
 Left 227 (49.5%) 226 (49.7%) 453 (49.6%)
 Right 232 (50.5%) 229 (50.3%) 461 (50.4%)
Completion of Neoadjuvant Treatment Protocol
 Yes 372 (81.0%) 353 (77.6%) 725 (79.3%)
 No 87 (19.0%) 102 (22.4%) 189 (20.7%)
structure_race
 AA 69 (15.0%) 51 (11.2%) 120 (13.1%)
 CA 352 (76.7%) 377 (82.9%) 729 (79.8%)
 HC 13 (2.8%) 4 (0.9%) 17 (1.9%)
 UN 25 (5.4%) 23 (5.1%) 48 (5.3%)
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